Menu
No results found.
Weekly Share Price & Valuation Overview
Senzime AB (publ)
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It provides TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue's opposition to carrying an alternating electrical current. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system and related digital hub for data transmission to hospital electronic patient journals; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Revenue growth ≥10% indicates solid top-line momentum.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- SEK 1.01B
- Enterprise Value Operating value: market cap + total debt − cash.
- SEK 890.74M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- SEK 80.64M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- SEK 32.92M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- SEK 0.62
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.96
- Shares Outstanding
- 157.22M
- Float Shares
- 109.71M
- Implied Shares Outstanding
- 161.85M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-1.14%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
40.83%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-1.57%
- ROA Return on assets: net income ÷ total assets.
-
-17.96%
- ROE Return on equity: net income ÷ shareholder equity.
-
-36.58%
- Revenue Growth Strong Year-over-year revenue growth.
-
72.30%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
4.29%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 5.03
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.04
- Total Cash Cash and equivalents.
- SEK 132.16M
- Total Debt Short + long-term interest-bearing debt.
- SEK 14.94M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- SEK -117.22M
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- SEK -103.29M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- SEK -82.28M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-128.09%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-102.03%
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.